Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Merck
Boehringer Ingelheim
Mallinckrodt
Baxter

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

ARCALYST Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: ARCALYST
Patents:22
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for ARCALYST
Recent Clinical Trials for ARCALYST

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Regeneron PharmaceuticalsPhase 0
Stanley CohenPhase 0
Regeneron PharmaceuticalsPhase 2

See all ARCALYST clinical trials

Company Disclosures: US Patents for ARCALYST

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2013-10-20 RX Orphan company
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2018-09-25 RX Orphan company
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2018-09-25 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for ARCALYST

These patents were identified by searching patent claims

Supplementary Protection Certificates for ARCALYST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
91680 Luxembourg   Start Trial 91680, EXPIRES: 20241023
SZ 15/2010 Austria   Start Trial PRODUCT NAME: RILONACEPT
SPC017/2010 Ireland   Start Trial SPC017/2010: 20101001, EXPIRES: 20240921
122017000101 Germany   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
17C1057 France   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
CR 2017 00061 Denmark   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196/001-8 20170627
300911 Netherlands   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
McKinsey
Baxter
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.